Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental chemo cocktail targets resistant leukemia

NCT ID NCT03150004

Terminated Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of chemotherapy drugs (cladribine, cytarabine, mitoxantrone, and G-CSF) in 53 adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that had come back or not responded to prior treatment. The goal was to see how many patients achieved complete remission with no detectable cancer cells. However, the trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cladribine, cytarabine, mitoxantrone, and G-CSF (CLAG-M regimen)
What this could lead to
If successful, this could offer a treatment option for people with hard-to-treat leukemia or MDS who have not responded to other therapies.
What could go wrong
The trial was terminated early, so results are limited. It is a small, single-center study, and the chemotherapy has significant side effects like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

  • Froedtert & the Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.